Header

UZH-Logo

Maintenance Infos

No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients


Lutterotti, A; Jelcic, I; Schulze, C; Schippling, S; Breiden, P; Mazzanti, B; Reinhardt, S; DiGioia, M; Repice, A; Massacesi, L; Sputtek, A; Salinas-Riester, G; Kroeger, N; Sospedra, M; Saccardi, R; Zander, A; Martin, R (2012). No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. Multiple Sclerosis Journal, 18(8):1188-1192.

Abstract

Autologous hematopoietic stem cell transplantation (aHSCT) has been used as a therapeutic approach in multiple sclerosis (MS). However, it is still unclear if the immune system that emerges from autologous CD34+ hematopoietic progenitor cells (HPC) of MS patients is pre-conditioned to re-develop the proinflammatory phenotype. The objective of this article is to compare the whole genome gene and microRNA expression signature in CD34+ HPC of MS patients and healthy donors (HD). CD34+ HPC were isolated from peripheral blood of eight MS patients and five HD and analyzed by whole genome gene expression and microRNA expression microarray. Among the differentially expressed genes (DEGs) only TNNT1 reached statistical significance (logFC=3.1, p<0.01). The microRNA expression was not significantly different between MS patients and HD. We did not find significant alterations of gene expression or microRNA profiles in CD34+ HPCs of MS patients. Our results support the use of aHSCT for treatment of MS.

Abstract

Autologous hematopoietic stem cell transplantation (aHSCT) has been used as a therapeutic approach in multiple sclerosis (MS). However, it is still unclear if the immune system that emerges from autologous CD34+ hematopoietic progenitor cells (HPC) of MS patients is pre-conditioned to re-develop the proinflammatory phenotype. The objective of this article is to compare the whole genome gene and microRNA expression signature in CD34+ HPC of MS patients and healthy donors (HD). CD34+ HPC were isolated from peripheral blood of eight MS patients and five HD and analyzed by whole genome gene expression and microRNA expression microarray. Among the differentially expressed genes (DEGs) only TNNT1 reached statistical significance (logFC=3.1, p<0.01). The microRNA expression was not significantly different between MS patients and HD. We did not find significant alterations of gene expression or microRNA profiles in CD34+ HPCs of MS patients. Our results support the use of aHSCT for treatment of MS.

Statistics

Citations

4 citations in Web of Science®
5 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 30 Nov 2012
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:30 Nov 2012 11:49
Last Modified:05 Apr 2016 16:06
Publisher:SAGE Publications
Series Name:Multiple Sclerosis
ISSN:1352-4585
Publisher DOI:https://doi.org/10.1177/1352458511434067
PubMed ID:22252466

Download